Renhe Pharmacy Co

Renhe Pharmacy Co Receivables

The Accounts Receivable of Renhe Pharmacy Co (000650.SZ) as of Oct 28, 2026 is 365.72 M CNY. In the previous year, Accounts Receivable was 402.37 M CNY — a change of -9.11% (lower).

Receivables

365.72 MCNY

YoY

-9.11%

Last updated:

Accounts Receivable of Renhe Pharmacy Co is 2024 365.72 M CNY. Accounts Receivable of Renhe Pharmacy Co was 2023 402.37 M CNY. It decreases by -9.11% lower compared to the previous year.

The Renhe Pharmacy Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
294.30 M CNY
Jan 1, 2018
369.10 M CNY
Jan 1, 2019
336.40 M CNY
Jan 1, 2020
297.30 M CNY
Jan 1, 2021
412.98 M CNY
Jan 1, 2022
348.27 M CNY
Jan 1, 2023
402.37 M CNY
Jan 1, 2024
365.72 M CNY
The Renhe Pharmacy Co Receivables history
YEARReceivablesYoY
365.72 MCNY-9.11%
402.37 MCNY+15.53%
348.27 MCNY-15.67%
412.98 MCNY+38.91%
297.30 MCNY-11.62%
336.40 MCNY-8.86%
369.10 MCNY+25.42%
294.30 MCNY+12.07%
262.60 MCNY+2.30%
256.70 MCNY+68.55%
152.30 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renhe Pharmacy Co Stock analysis

What does Renhe Pharmacy Co do? Renhe Pharmacy Co., Ltd. generates revenue through the manufacturing and distribution of pharmaceutical products including capsules, granules, tablets, powder, injections, suppositories, and ointment. The company operates in the domestic market, focusing on medical industrial manufacturing and medical merchandising. Its primary customers are domestic healthcare providers and retail outlets purchasing health-related products for distribution or direct consumer use. The firm's product portfolio spans various dosage forms essential for medical treatment and patient care. The company's business model relies on both wholesale and retail channels within China, serving the domestic pharmaceutical market. Renhe Pharmacy's manufacturing segment produces a wide range of medication forms, while its merchandising division handles the sale of health-related products. This dual approach allows the company to capture value across the pharmaceutical supply chain from production to consumer. Renhe Pharmacy Co., Ltd. serves the Chinese domestic market exclusively, with its operations centered on medical industrial manufacturing and medical merchandising. The company's revenue streams are derived from the sale of its diverse product range to healthcare institutions, pharmacies, and consumers through its retail network. This integrated approach ensures consistent market presence and customer reach within its geographic focus. Renhe Pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renhe Pharmacy Co stock

Accounts Receivable of Renhe Pharmacy Co is 365.72 M CNY in 2024.

Accounts Receivable of Renhe Pharmacy Co changed from 402.37 M CNY to 365.72 M CNY, representing a -9.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Renhe Pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Renhe Pharmacy Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Renhe Pharmacy Co

All Key Metrics — Renhe Pharmacy Co